NEW YORK--(BUSINESS WIRE)--Rhinix ApS announced today that it is looking for strategic partners to bring Rhinix™, a side effect free alternative to medication for patients with respiratory allergies, into the US market.
Rhinix ApS is a privately held company focused on helping patients with respiratory allergies who are not well-controlled by today’s drug options or who wish to get off day-to-day medication. In collaboration with the Trade Council at the Royal Danish Consulate General, Rhinix ApS has begun its efforts to bring Rhinix™ to the US, by looking for a strong strategic partner capable of a nationwide launch of Rhinix™.
Rhinix™ is a nasal filter that removes allergens from the inhaled air without impeding normal breathing. Preliminary results from an ongoing study indicate that Rhinix™ might be able to help patients with respiratory allergies such as hay fever.
Approximately 20% of the population in industrialized countries suffers from respiratory allergies and the number is expected to increase. Total value growth for antihistamines was 85.6% from 2006-2011 in the US.
Preliminary results from an ongoing study indicate that Rhinix™ may have the potential to reduce overall nasal symptoms related to hay fever as well as hay fever related throat irritation.
Rhinix™ is easily inserted and, when inserted correctly, nearly invisible. Rhinix™ can be used both in professional and social settings, as well as during sleep. 90% of study participants were interested in using the device and 98% of study participants evaluated the product as safe to use.
Joseph Hernandez, Senior Advisor at the Royal Danish Consulate General, said, "The launch of Rhinix™ has the potential to improve quality of life for millions of people suffering from respiratory allergies and revolutionize the market for allergy medications. It is estimated that 25% of people suffering from respiratory allergies – 10 million people in the US alone - are not adequately controlled with the treatment options available today.”
Peter Kenney Hansen, CEO of Rhinix ApS, said, "We are excited about the prospect of introducing Rhinix™ nasal filters to the US market. Having been inspired by both the contact lens and hearing aid industries on how to develop wearable products, we believe that we have cracked the code on how to make nasal filters a relevant alternative to standard hay fever treatment options.”
About Rhinix ApS
Rhinix ApS is a Danish clinical-stage medical device company focused on the development and commercialisation of nasal filters for the treatment of allergic rhinitis (hay fever).
About the Trade Council at the Royal Danish Consulate General
The Trade Council works to generate opportunities for Danish business in the US and assists Danish companies in realizing their potential on the US market.